In € million

 

 

 

IFRS(1)

 

Underlying

 

Notes

 

2017

 

2016

 

% yoy

 

2017

 

2016

 

% yoy

(1)

A full reconciliation of IFRS and underlying income statement data can be found in section 5 of the Business Review.

(2)

Recommended 2017 dividend, pending General Shareholders meeting on May 8, 2018.

(3)

Underlying net debt includes the perpetual hybrid bonds, accounted for as equity under IFRS.

(4)

Ratio of underlying net financial debt to underlying EBITDA, adjusted for discontinued operations.

(5)

CFROI (Cash Flow Return On Investment) and Research & Innovation reference figures are provided on a non-restated basis.

Net sales

 

B1

 

10,125

 

9,569

 

5.8%

 

10,125

 

9,569

 

5.8%

Net operating costs, excluding depreciation & amortization

 

B2

 

 

 

n.m.

 

(7,894)

 

(7,493)

 

(5.4)%

EBITDA

 

B3

 

2,029

 

1,932

 

5.1%

 

2,230

 

2,075

 

7.5%

EBITDA margin

 

B3

 

 

 

 

 

 

 

22%

 

22%

 

0.3pp

Depreciation, amortization & impairments

 

B4

 

(1,054)

 

(1,074)

 

1.9%

 

(704)

 

(672)

 

(4.7)%

EBIT

 

 

 

976

 

858

 

14%

 

1,527

 

1,403

 

8.8%

Net financial charges

 

B5

 

(298)

 

(334)

 

11%

 

(394)

 

(464)

 

15%

Income taxes

 

B6

 

197

 

68

 

n.m.

 

(299)

 

(272)

 

(10)%

Tax rate

 

B6

 

 

 

 

 

 

 

27.5%

 

30.3%

 

(2.8)pp

Profit (loss) from discontinued operations

 

B7

 

241

 

82

 

n.m.

 

159

 

240

 

(34)%

(Profit) loss attributable to non-controlling interests

 

 

 

(56)

 

(53)

 

3.9%

 

(54)

 

(61)

 

(11)%

Profit attributable to Solvay share

 

 

 

1,061

 

621

 

71%

 

939

 

846

 

11%

Basic earnings per share (in €)

 

B24

 

10.27

 

6.01

 

71%

 

9.08

 

8.19

 

11%

of which from continuing operations

 

B24

 

7.97

 

5.34

 

49%

 

7.59

 

6.02

 

26%

Dividend(2)

 

B25

 

3.60

 

3.45

 

4.3%

 

3.60

 

3.45

 

4.3%

Capex

 

B8

 

(822)

 

(981)

 

16%

 

(822)

 

(981)

 

16%

of which from continuing operations

 

B8

 

(716)

 

(839)

 

15%

 

(716)

 

(839)

 

15%

Cash conversion

 

B8

 

 

 

 

 

 

 

68%

 

60%

 

8.3pp

Free cash flow

 

B9

 

871

 

876

 

(0.5)%

 

871

 

876

 

(0.5)%

of which from continuing operations

 

B9

 

782

 

658

 

19%

 

782

 

658

 

19%

Net working capital

 

B10

 

1,414

 

1,396

 

1.3%

 

1,414

 

1,396

 

1.3%

Net working capital/sales

 

B10

 

 

 

 

 

 

 

 

 

(1.5)%

Net debt(3)

 

B11

 

(3,146)

 

(4,356)

 

28%

 

(5,346)

 

(6,556)

 

18%

Underlying leverage ratio

 

B11

 

 

 

 

 

 

 

2.17

 

2.60

 

(0.43)

CFROI(5)

 

B12

 

 

 

 

 

 

 

6.9%

 

6.3%

 

0.6pp

Research & innovation(5)

 

B13

 

 

 

 

 

 

 

(325)

 

(350)

 

7.0%

Research & innovation intensity(5)

 

B13

 

 

 

 

 

 

 

3.2%

 

3.2%